The ongoing phase II MEDIOLA trial is evaluating the efficacy of the PD-L1 inhibitor durvalumab and the PARP inhibitor olaparib in cancers with BRCA1 /2 mutations, with results showing a 12-week DCR of 80% (49). The gene discussed is CD274; the disease is cancer.